Saturday almost ushered in David White’s last dose of Tasigna, a pill he was receiving free of charge to treat his chronic myeloid leukemia.
The 31-year-old Beaufort resident was participating in a clinical trial with drug maker Novartis, and he qualified for more of the $2,300-per-month drug — if he could prove his date of eligibility for Medicare. That day falls in August 2014, two years after White’s illness forced him to file for disability.
As proof, Novartis required an official document from the Social Security Administration, at a time when the agency was severely slowed by a 16-day, partial government shutdown.
It was only once the shutdown ended, following Congress’ vote to fund the government through Jan. 15, that White got what he needed to secure his lifesaving treatments.